Nottingham, UK-based Albumedix, a science-driven biotechnology company, announced on Tuesday that it will be acquired by Germany-based Sartorius, a leader in laboratory and bioprocessing technologies for the biopharmaceutical industry.
Sartorius, through its French-listed subgroup Sartorius Stedim Biotech, will acquire all outstanding shares of Albumedix Ltd. for nearly £415M (approximately €491.15M). The deal is expected to close before the end of Q3 2022.
By acquiring Albumedix, Sartorius will be able to offer science-enabled solutions for the whole value chain of advanced therapy by adding complementary technologies and synergistic competencies to their solution space.
What does Albumedix offer?
Established in 1984, Albumedix is a science-driven company that provides albumin-enabled solutions. The company claims to have supported its life-science partners to deliver millions of safe doses of clinical and marketed therapeutics, globally.
Albumedix aims at the development and commercialisation of advanced therapies and next-generation biopharmaceuticals for the benefit of people worldwide. Its solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin), client-centric development and compliance services, and drug-enhancing technologies (Veltis).
CEO Jonas S. Moller says, “We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers. We have been highly impressed with Sartorius’ knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius will bring tremendous value by strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform.”
The company will continue to be led by CEO Jonas S. Moller and the executive management team.
Aim of this acquisition
According to a statement, the deal underscores a market shift toward defined and high-quality manufacturing options for advanced therapeutic products, which rely heavily on recombinant human albumin.
The expanding Albumedix Campus in Nottingham, UK, will be developed as a centre of excellence in Sartorius, dedicated to bio-innovation and GMP-compliant manufacture of essential raw materials. Albumedix will become a component of the Bioprocess Solutions Division inside Sartorius.
Sartorius also plans to make quick investments in Albumedix’s platform for producing recombinant proteins and innovative capabilities.
Rene Faber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius, says, “Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones.”
About Sartorius
Sartorius empowers scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and affordable medicine.
The company says it has been growing annually by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, it earned sales revenue of nearly €3.45B. And at the end of 2021, nearly 14,000 people were employed at Sartorius’ approximately 60 manufacturing and sales sites, serving customers globally.
01
From port to startup fort: How Lars Crama is ‘Making it Happen’ in Rotterdam